Mr. Chair, the idea that you make the provision of information connect the registration of clinical trials with the validity of a market authorization.... There's a lot to look at there.
A market authorization allows a drug to be given to a patient. These are often very needed. If you're prolonging life with a cancer drug, having technically failed to register and thereby automatically cancelling a licence, or going to the validity of a licence, is a moment of gravity.
There are other measures in this instrument, or at least they're proposed—to go for large fines, and so on—to discipline company behaviour around transparency. It's just as a cautionary note.
The other thing is that in the regulations, as a matter of course as the minister goes along, Health Canada does want to see every study done on the drug and would want to put that in the regulatory requirements. That goes to the drug approval itself. We would suggest that's the appropriate placement of a requirement of this nature.